Breaking News Instant updates and real-time market news.

TKPYY

Takeda Pharmaceutical

$24.68

-0.275 (-1.10%)

, SHPG

Shire

$156.43

2.91 (1.90%)

12:20
04/06/18
04/06
12:20
04/06/18
12:20

Takeda says CEO comments over Shire aligned with previous statements

Takeda Pharmaceutical (TKPYY) notes media reports about comments attributed to Takeda's CEO Christophe Weber regarding the company's possible offer for Shire (SHPG). Takeda confirms that Weber's comments were "aligned with the statements in the company's previous press releases." The company added, "As set out in the press releases 'Takeda Statement Regarding Shire plc' on March 28, 2018 in English and 'Takeda's official statement on Shire's stock fluctuation' on March 29, 2018 in Japanese, clearly defined strategic and financial objectives are core to Takeda's disciplined approach to acquisitions, including in relation to its dividend policy and credit rating, which are well-established. Any potential offer for Shire, if made, would have to align with this strict investment criteria."

TKPYY

Takeda Pharmaceutical

$24.68

-0.275 (-1.10%)

SHPG

Shire

$156.43

2.91 (1.90%)

  • 21

    Dec

TKPYY Takeda Pharmaceutical
$24.68

-0.275 (-1.10%)

10/03/17
JMPS
10/03/17
NO CHANGE
Target $25
JMPS
Outperform
Myovant Phase 3 results further de-risk ongoing trials, says JMP Securities
After Myovant Sciences (MYOV) and partner Takeda (TKPYY) announced a Japanese study evaluating the efficacy and safety of relugolix to treat uterine fibroids met its primary endpoint, JMP Securities analyst Jason Butler said the results represent a "best case outcome" and have a clear positive read through to ongoing international Phase 3 trials in uterine fibroids and endometriosis. The analyst, who increased his view of the probability of success in UF and EM, raised his price target on Myovant shares to $25 from $23 and keeps an Outperform rating on the stock.
01/16/18
BTIG
01/16/18
DOWNGRADE
BTIG
Neutral
TiGenix downgraded at BTIG to Neutral on valuation
As noted earlier, BTIG analyst Timothy Chiang downgraded TiGenix (TIG) to Neutral from Buy, saying the run-up of 81% year to date in the stock price has exceeded his target and warrants a move to the sidelines. Chiang believes that the acquisition offer by Takeda (TKPYY) will pass the required regulatory review of TiGenix lead product Alofisei in the E.U., adding that there is now less than 5% difference in the stock price relative to the Takeda offer.
03/28/18
BOFA
03/28/18
NO CHANGE
BOFA
Buy
Still considerable value in Shire even in no Takeda bid scenario, says BofA/Merrill
BofA/Merrill analyst Graham Parry notes that Takeda (TKPYY) has said in a statement that it is considering an approach for Shire (SHPG) but that the consideration is at a preliminary and exploratory stage and no approach has been made to the board of Shire. The analyst continues to see considerable value in Shire with concerns over hemophilia more than priced into the stock and upsides from pipeline, notably SHP643 for HAE and SHP647 for Ulcerative colitis and Crohns, and the value of its plasma/immunology franchise overlooked. Even in a no bid scenario, Parry believes passage through hemophilia overhangs and increased awareness of the value in these assets should see Shire trade higher on 12-month view. He reiterates a Buy rating on Shire's shares.
03/29/18
JEFF
03/29/18
NO CHANGE
Target $172
JEFF
Buy
Shire investors may be amenable to $50B-plus bid, says Jefferies
With challenges in the hemophilia market near term, Shire (SHPG) investors could be amenable to another $50B-plus bid, similar to AbbVie's (ABBV) 2014 offer, Jefferies analyst David Steinberg tells investors in a research note. This would represent a 35% premium to Shire's recent near five-year low valuation, the analyst writes. He says "it remains to be seen" how Takeda Pharmaceutical (TKPYY) could structure a transaction for Shire given the companies' similar equity valuations. The analyst finds it possible that Takeda's disclosed interest could spark competitive bids from large cap pharma companies. He keeps a Buy rating on Shire with a $172 price target.
SHPG Shire
$156.43

2.91 (1.90%)

02/22/18
BOFA
02/22/18
NO CHANGE
BOFA
Buy
Shire post results weakness overdone, says BofA/Merrill
BofA/Merrill analyst Graham Parry believes Shire post results weakness is overdone and says shares remain undervalued. The analyst argued that cons EPS cuts are already priced in, and reiterates a Buy rating on the shares.
03/07/18
HCWC
03/07/18
NO CHANGE
Target $12
HCWC
Buy
Caladrius price target raised to $12 from $7 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Caladrius Biosciences (CLBS) to $12 after the company acquired from Shire (SHPG) an exclusive worldwide license to data and regulatory filings for a late-stage CD34+ cell therapy program for the treatment of chronic myocardial ischemia targeting refractory angina. The deal "significantly enriches" Caladrius' existing pipeline and should provide an "additional attractive shot on goal" in the coming years, Selvaraju tells investors in a research note. He increased his valuation of the company to $120M from $60M and reiterates a Buy rating on the shares.

TODAY'S FREE FLY STORIES

KBR

KBR

$17.09

-0.06 (-0.35%)

06:04
04/19/18
04/19
06:04
04/19/18
06:04
Hot Stocks
KBR acquires Carillion's interests in Aspire Defence joint venture »

KBR announced, following…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 14

    Jun

  • 25

    Jun

GTLS

Chart Industries

$60.57

-0.22 (-0.36%)

06:03
04/19/18
04/19
06:03
04/19/18
06:03
Earnings
Chart Industries reports Q1 adjusted EPS 23c, consensus 19c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Apr

  • 17

    May

  • 29

    May

  • 29

    Aug

  • 30

    Aug

BBT

BB&T

$50.62

-0.47 (-0.92%)

06:03
04/19/18
04/19
06:03
04/19/18
06:03
Earnings
BB&T reports Q1 EPS 94c, consensus 92c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Apr

  • 24

    Apr

GOOG

Alphabet

$1,072.25

-2.17 (-0.20%)

, GOOGL

Alphabet Class A

$1,075.28

-4.12 (-0.38%)

06:02
04/19/18
04/19
06:02
04/19/18
06:02
Periodicals
Google Pay surpasses 100M downloads on Play Store, Android Police says »

Google Pay, called…

GOOG

Alphabet

$1,072.25

-2.17 (-0.20%)

GOOGL

Alphabet Class A

$1,075.28

-4.12 (-0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 23

    Apr

INTC

Intel

$53.61

0.08 (0.15%)

06:01
04/19/18
04/19
06:01
04/19/18
06:01
Periodicals
Intel plans to shut down New Devices Group, The Information reports »

Intel plans to shut down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADMS

Adamas Pharmaceuticals

$25.86

0.86 (3.44%)

05:59
04/19/18
04/19
05:59
04/19/18
05:59
Hot Stocks
Adamas Pharmaceuticals announces final results from GOCOVRI Phase 3 study »

Adamas Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Apr

  • 25

    Apr

  • 25

    Apr

  • 12

    Jun

TSLA

Tesla

$293.42

5.8 (2.02%)

05:55
04/19/18
04/19
05:55
04/19/18
05:55
Hot Stocks
Tesla batteries delivering power at 662 locations in Puerto Rico, Musk says »

Tesla CEO Elon Musk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JPM

JPMorgan

$109.31

-0.9 (-0.82%)

05:55
04/19/18
04/19
05:55
04/19/18
05:55
Hot Stocks
JPMorgan Chase announces branch expansion in Greater Washington DC »

JPMorgan Chase announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

  • 30

    May

  • 13

    Jul

  • 12

    Oct

ICLK

iClick Interactive Asia

$7.76

0.19 (2.51%)

05:55
04/19/18
04/19
05:55
04/19/18
05:55
Conference/Events
iClick Interactive Asia management to meet with Roth Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Apr

  • 20

    Apr

SBNY

Signature Bank

$135.08

-1.99 (-1.45%)

05:52
04/19/18
04/19
05:52
04/19/18
05:52
Hot Stocks
Signature Bank reports Q1 EPS ex-items $2.69, consensus $2.67 »

Reports Q1 book value per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Apr

  • 25

    Apr

SCCO

Southern Copper

$57.33

0.745 (1.32%)

05:50
04/19/18
04/19
05:50
04/19/18
05:50
Downgrade
Southern Copper rating change  »

Southern Copper…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

FOXA

21st Century Fox

$37.32

-0.22 (-0.59%)

, DIS

Disney

$101.21

-1 (-0.98%)

05:49
04/19/18
04/19
05:49
04/19/18
05:49
Hot Stocks
21st Century Fox rejected rival bid of $34.41 per share for assets »

Disney (DIS) disclosed…

FOXA

21st Century Fox

$37.32

-0.22 (-0.59%)

DIS

Disney

$101.21

-1 (-0.98%)

CMCSA

Comcast

$33.28

0.02 (0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 08

    May

  • 09

    May

NTRS

Northern Trust

$106.38

-0.04 (-0.04%)

05:47
04/19/18
04/19
05:47
04/19/18
05:47
Hot Stocks
Northern Trust enters partnership with The Northern Pool »

The Northern Pool has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$81.72

-0.09 (-0.11%)

, AMGN

Amgen

$175.14

0.19 (0.11%)

05:36
04/19/18
04/19
05:36
04/19/18
05:36
Hot Stocks
Novartis appoints John Tsai as Chief Medical Officer, Head of GDD »

Novartis (NVS) announced…

NVS

Novartis

$81.72

-0.09 (-0.11%)

AMGN

Amgen

$175.14

0.19 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 24

    Apr

  • 30

    Apr

  • 17

    May

  • 21

    May

  • 28

    May

  • 05

    Jun

AMZN

Amazon.com

$1,527.24

23.92 (1.59%)

05:36
04/19/18
04/19
05:36
04/19/18
05:36
Recommendations
Amazon.com analyst commentary  »

Amazon online retail…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

NVS

Novartis

$81.72

-0.09 (-0.11%)

05:34
04/19/18
04/19
05:34
04/19/18
05:34
Earnings
Novartis confirms FY18 revenue guidance of growth of low to mid single-digit »

Novartis noted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 17

    May

  • 21

    May

  • 05

    Jun

NVS

Novartis

$81.72

-0.09 (-0.11%)

05:34
04/19/18
04/19
05:34
04/19/18
05:34
Hot Stocks
Novartis reports Q1 Alcon sales of $1.8B »

Alcon net sales were…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 17

    May

  • 21

    May

  • 05

    Jun

RDN

Radian Group

$15.36

-0.91 (-5.59%)

05:30
04/19/18
04/19
05:30
04/19/18
05:30
Recommendations
Radian Group analyst commentary  »

Radian Group price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

NVS

Novartis

$81.72

-0.09 (-0.11%)

05:29
04/19/18
04/19
05:29
04/19/18
05:29
Hot Stocks
Novartis Q1 results continue to demonstrate benefit from turnaround plan actions »

Novartis noted, Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 17

    May

  • 21

    May

  • 05

    Jun

MTG

MGIC Investment

$10.50

-0.275 (-2.55%)

05:29
04/19/18
04/19
05:29
04/19/18
05:29
Downgrade
MGIC Investment rating change  »

MGIC Investment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESNT

Essent Group

$34.83

-2.045 (-5.55%)

, MTG

MGIC Investment

$10.50

-0.275 (-2.55%)

05:28
04/19/18
04/19
05:28
04/19/18
05:28
Downgrade
Essent Group, MGIC Investment, Radian Group rating change  »

Essent Group downgraded…

ESNT

Essent Group

$34.83

-2.045 (-5.55%)

MTG

MGIC Investment

$10.50

-0.275 (-2.55%)

RDN

Radian Group

$15.36

-0.91 (-5.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 04

    May

NVS

Novartis

$81.72

-0.09 (-0.11%)

05:27
04/19/18
04/19
05:27
04/19/18
05:27
Hot Stocks
Novartis reports Q1 Sandoz net sales of $2.5B »

Sandoz net sales were…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 17

    May

  • 21

    May

  • 05

    Jun

NVS

Novartis

$81.72

-0.09 (-0.11%)

05:25
04/19/18
04/19
05:25
04/19/18
05:25
Earnings
Novartis reports Q1 core EPS $1.28, consensus $1.29 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 17

    May

  • 21

    May

  • 05

    Jun

PG

Procter & Gamble

$78.19

-0.23 (-0.29%)

, TEVA

Teva

$17.91

0.065 (0.36%)

05:23
04/19/18
04/19
05:23
04/19/18
05:23
Hot Stocks
Procter & Gamble acquires Consumer Health business of Merck KGaA for EUR 3.4B »

Procter & Gamble (PG)…

PG

Procter & Gamble

$78.19

-0.23 (-0.29%)

TEVA

Teva

$17.91

0.065 (0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 27

    Apr

  • 18

    May

  • 05

    Jun

  • 16

    Jun

GOL

GOL Linhas

$13.51

0.72 (5.63%)

05:22
04/19/18
04/19
05:22
04/19/18
05:22
Downgrade
GOL Linhas rating change  »

GOL Linhas downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.